MEDROXYPROGESTERONE vs MEDROXYPROGESTERONE ACETATE

Compare MEDROXYPROGESTERONE (Medroxyprogesterone) and MEDROXYPROGESTERONE ACETATE (MEDROXYPROGESTERONE ACETATE) — clinical data, side effects, and patient experiences.

MEDROXYPROGESTERONE

Medroxyprogesterone, Provera, Depo-Provera · Hormone

How it works

Other agent

Approved for

See full prescribing information

OralTablet

MEDROXYPROGESTERONE ACETATE

MEDROXYPROGESTERONE ACETATE · Hormone

How it works

12.1 Mechanism of Action Medroxyprogesterone acetate (MPA) injectable suspension, inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulati...

Approved for

longer than 2 years) birth control method unless other options are considered inadequate. (1

5.1)

IntramuscularTablet

Quick Comparison

MEDROXYPROGESTERONEMEDROXYPROGESTERONE ACETATE

Drug Class

Hormone

Route

Oral

Intramuscular

Half-Life

—

FDA Approved

—

Pregnancy

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

MEDROXYPROGESTERONE

Drug Not Working

0.1-1%

Nausea

0.1-1%

Headache

0.1-1%

Depression

0.1-1%

Fatigue

0.1-1%

Anxiety

0.1-1%

Weight Gain

0.1-1%

Dizziness

0.1-1%

MEDROXYPROGESTERONE ACETATE

Drug Not Working

0.1-1%

Nausea

0.1-1%

Headache

0.1-1%

Depression

0.1-1%

Fatigue

0.1-1%

Anxiety

0.1-1%

Weight Gain

0.1-1%

Dizziness

0.1-1%

FDA Warnings

MEDROXYPROGESTERONE

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
( See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia
) The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5
( See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders

MEDROXYPROGESTERONE ACETATE

5 WARNINGS AND PRECAUTIONS Thromboembolic Disorders: Discontinue medroxyprogesterone acetate injectable suspension in patients who develop thrombosis
2 ) Cancer Risks: Monitor women with a strong family history of breast cancer carefully
It is unknown if use of medroxyprogesterone acetate injectable suspension by younger women will reduce peak bone mass and increase the risk for osteoporotic fracture in later life
Other birth control methods should be considered in the risk/benefit analysis for the use of medroxyprogesterone acetate injectable suspension in women with osteoporosis risk factors

Clinical Trial Data

No head-to-head clinical studies found for MEDROXYPROGESTERONE vs MEDROXYPROGESTERONE ACETATE.

MEDROXYPROGESTERONE vs MEDROXYPROGESTERONE ACETATE: What You Should Know

Key Differences

Both MEDROXYPROGESTERONE and MEDROXYPROGESTERONE ACETATE belong to the Hormone class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. MEDROXYPROGESTERONE is administered via Oral, whereas MEDROXYPROGESTERONE ACETATE uses Intramuscular. Route of administration can affect onset of action and patient adherence.

Safety Considerations

MEDROXYPROGESTERONE carries 4 FDA warnings. MEDROXYPROGESTERONE ACETATE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

LEVONORGESTREL AND ETHINYL ESTRADIOL vs MEDROXYPROGESTERONE ACETATE→MEDROXYPROGESTERONE ACETATE vs NORGESTIMATE AND ETHINYL ESTRADIOL→ESTRADIOL VALERATE AND ESTRADIOL VALERATE vs MEDROXYPROGESTERONE ACETATE→DESOGESTREL AND ETHINYL ESTRADIOL vs MEDROXYPROGESTERONE ACETATE→ETONOGESTREL AND ETHINYL ESTRADIOL vs MEDROXYPROGESTERONE ACETATE→LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS vs MEDROXYPROGESTERONE ACETATE→

Loading comparison data...

MEDROXYPROGESTERONE vs MEDROXYPROGESTERONE ACETATE

Compare MEDROXYPROGESTERONE (Medroxyprogesterone) and MEDROXYPROGESTERONE ACETATE (MEDROXYPROGESTERONE ACETATE) — clinical data, side effects, and patient experiences.

MEDROXYPROGESTERONE

Medroxyprogesterone, Provera, Depo-Provera · Hormone

How it works

Other agent

Approved for

See full prescribing information

OralTablet

MEDROXYPROGESTERONE ACETATE

MEDROXYPROGESTERONE ACETATE · Hormone

How it works

12.1 Mechanism of Action Medroxyprogesterone acetate (MPA) injectable suspension, inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulati...

Approved for

longer than 2 years) birth control method unless other options are considered inadequate. (1

5.1)

IntramuscularTablet

Quick Comparison

MEDROXYPROGESTERONEMEDROXYPROGESTERONE ACETATE

Drug Class

Hormone

Route

Oral

Intramuscular

Half-Life

—

FDA Approved

—

Pregnancy

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

MEDROXYPROGESTERONE

Drug Not Working

0.1-1%

Nausea

0.1-1%

Headache

0.1-1%

Depression

0.1-1%

Fatigue

0.1-1%

Anxiety

0.1-1%

Weight Gain

0.1-1%

Dizziness

0.1-1%

MEDROXYPROGESTERONE ACETATE

Drug Not Working

0.1-1%

Nausea

0.1-1%

Headache

0.1-1%

Depression

0.1-1%

Fatigue

0.1-1%

Anxiety

0.1-1%

Weight Gain

0.1-1%

Dizziness

0.1-1%

FDA Warnings

MEDROXYPROGESTERONE

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
( See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia
) The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5
( See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders

MEDROXYPROGESTERONE ACETATE

5 WARNINGS AND PRECAUTIONS Thromboembolic Disorders: Discontinue medroxyprogesterone acetate injectable suspension in patients who develop thrombosis
2 ) Cancer Risks: Monitor women with a strong family history of breast cancer carefully
It is unknown if use of medroxyprogesterone acetate injectable suspension by younger women will reduce peak bone mass and increase the risk for osteoporotic fracture in later life
Other birth control methods should be considered in the risk/benefit analysis for the use of medroxyprogesterone acetate injectable suspension in women with osteoporosis risk factors

Clinical Trial Data

No head-to-head clinical studies found for MEDROXYPROGESTERONE vs MEDROXYPROGESTERONE ACETATE.

MEDROXYPROGESTERONE vs MEDROXYPROGESTERONE ACETATE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.